201 related articles for article (PubMed ID: 38242440)
1. Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.
Sung AD; Koll T; Gier SH; Racioppi A; White G; Lew M; Free M; Agarwal P; Bohannon LM; Johnson EJ; Selvan B; Babushok DV; Frey NV; Gill SI; Hexner EO; Martin M; Perl AE; Pratz KW; Luger SM; Chao NJ; Fisher AL; Stadtmauer EA; Porter DL; Loren AW; Bhatt VR; Gimotty PA; McCurdy SR
Transplant Cell Ther; 2024 Apr; 30(4):415.e1-415.e16. PubMed ID: 38242440
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of pre-transplant frailty and mental distress in hematopoietic cell transplantation and association with clinical outcomes.
Singh S; Cao Q; Demorest C; He F; Kramer A; Holtan S; Juckett M; Ramesh V; Arora M; Maakaron J; Weisdorf D; Jurdi NE
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38838780
[TBL] [Abstract][Full Text] [Related]
3. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
4. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients.
Pamukcuoglu M; Bhatia S; Weisdorf DJ; DeFor TE; Ustun C; Nayar M; Holtan SG; Jurdi NE; Thyagarajan B; Brunstein CG; Bachanova V; Warlick ED; Severseike B; Te HS; Lund T; Arora M
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2454-2460. PubMed ID: 31394273
[TBL] [Abstract][Full Text] [Related]
7. Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant.
Fernández-Caballero M; Jiménez Lorenzo MJ; Morgades de la Fe M; Ferrà Coll C; Vives Polo S; Abril Sabater L; Navarro Ferrando JT; Ribera Santasusana JM
Med Clin (Barc); 2022 May; 158(10):451-457. PubMed ID: 34404519
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
[TBL] [Abstract][Full Text] [Related]
9. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
[TBL] [Abstract][Full Text] [Related]
10. HCT frailty scale for younger and older adults undergoing allogeneic hematopoietic cell transplantation.
Salas MQ; Atenafu EG; Pasic I; Bascom O; Wilson L; Lam W; Law AD; Chen C; Novitzky-Basso I; Kim DDH; Gerbitz A; Viswabandya A; Michelis FV; Lipton JH; Mattsson J; Alibhai SMH; Kumar R
Bone Marrow Transplant; 2023 Nov; 58(11):1237-1246. PubMed ID: 37620424
[TBL] [Abstract][Full Text] [Related]
11. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S
J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255
[TBL] [Abstract][Full Text] [Related]
12. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
[TBL] [Abstract][Full Text] [Related]
13. Frailty in Patients with Chronic Graft-versus-Host Disease.
Rashid N; Arora M; Jurdi NE; Onstad L; Pidala JA; Flowers ME; Lee SJ
Transplant Cell Ther; 2023 Jun; 29(6):367-374. PubMed ID: 36921916
[TBL] [Abstract][Full Text] [Related]
14. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
[TBL] [Abstract][Full Text] [Related]
15. Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients.
Jiang JL; Gao WH; Wang LN; Wan M; Wang L; Hu J
Transplant Cell Ther; 2023 Aug; 29(8):512.e1-512.e8. PubMed ID: 37263418
[TBL] [Abstract][Full Text] [Related]
16. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
[TBL] [Abstract][Full Text] [Related]
17. Clinical Impact of Pretransplantation Physical Function on Transplantation after Allogeneic Hematopoietic Cell Transplantation in Older Adults.
Gomyo A; Kimura SI; Suzuki J; Ishikawa T; Meno T; Matsuoka A; Nakamura Y; Kawamura M; Kawamura S; Takeshita J; Yoshino N; Misaki Y; Yoshimura K; Okada Y; Akahoshi Y; Tamaki M; Kusuda M; Kameda K; Wada H; Sato M; Tanihara A; Sekine K; Nakasone H; Kako S; Kanda Y
Transplant Cell Ther; 2023 Nov; 29(11):721.e1-721.e8. PubMed ID: 37643718
[TBL] [Abstract][Full Text] [Related]
18. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
19. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.
Bejanyan N; Zhang M; Bo-Subait K; Brunstein C; Wang H; Warlick ED; Giralt S; Nishihori T; Martino R; Passweg J; Dias A; Copelan E; Hale G; Gale RP; Solh M; Kharfan-Dabaja MA; Diaz MA; Ganguly S; Gore S; Verdonck LF; Hossain NM; Kekre N; Savani B; Byrne M; Kanakry C; Cairo MS; Ciurea S; Schouten HC; Bredeson C; Munker R; Lazarus H; Cahn JY; van Der Poel M; Rizzieri D; Yared JA; Freytes C; Cerny J; Aljurf M; Palmisiano ND; Pawarode A; Bacher VU; Grunwald MR; Nathan S; Wirk B; Hildebrandt GC; Seo S; Olsson RF; George B; de Lima M; Hourigan CS; Sandmaier BM; Litzow M; Kebriaei P; Saber W; Weisdorf D
Transplant Cell Ther; 2021 Jan; 27(1):68.e1-68.e9. PubMed ID: 33010430
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
